EXTON, Pa., Oct. 13, 2022 /PRNewswire/ -- TNF inhibitors continue to be the mainstay for treating psoriatic arthritis (PsA), largely driven by the gold standards, etanercept and adalimumab. However, the recent entrance of IL-23 inhibitors (Janssen's Tremfya and AbbVie's Skyrizi) have an opportunity to impact a once relatively stable market.